A5075417603- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Gastric Cancer Management and Outcomes
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- TGF-β signaling in diseases
- Colorectal Cancer Treatments and Studies
- Cancer Research and Treatments
- Esophageal Cancer Research and Treatment
- Genetics, Bioinformatics, and Biomedical Research
- Lymphoma Diagnosis and Treatment
- Telomeres, Telomerase, and Senescence
- Adipokines, Inflammation, and Metabolic Diseases
- Gene expression and cancer classification
- Radiomics and Machine Learning in Medical Imaging
- Adipose Tissue and Metabolism
- Mitochondrial Function and Pathology
- Cancer Genomics and Diagnostics
- Chronic Lymphocytic Leukemia Research
- Advanced Breast Cancer Therapies
- Venous Thromboembolism Diagnosis and Management
- Multiple and Secondary Primary Cancers
- Biliary and Gastrointestinal Fistulas
- Glioma Diagnosis and Treatment
- Hepatocellular Carcinoma Treatment and Prognosis
University of Geneva
2024
Hospital Universitario Virgen Macarena
2016-2023
Universitat Politècnica de Catalunya
2020-2023
Barcelona Supercomputing Center
2020-2023
University of Oulu
2020
Sarah Cannon
2017-2018
Florida Hospital Cancer Institute
2017-2018
Tennessee Oncology
2017-2018
Moffitt Cancer Center
2017-2018
University of Glasgow
2017
Most patients with locally advanced, unresectable, non-small-cell lung cancer (NSCLC) have disease progression despite definitive chemoradiotherapy (chemotherapy plus concurrent radiation therapy). This phase 3 study compared the anti-programmed death ligand 1 antibody durvalumab as consolidation therapy placebo in stage III NSCLC who did not after two or more cycles of platinum-based chemoradiotherapy.
An earlier analysis in this phase 3 trial showed that durvalumab significantly prolonged progression-free survival, as compared with placebo, among patients stage III, unresectable non-small-cell lung cancer (NSCLC) who did not have disease progression after concurrent chemoradiotherapy. Here we report the results for second primary end point of overall survival.We randomly assigned patients, a 2:1 ratio, to receive intravenously, at dose 10 mg per kilogram body weight, or matching placebo...
The phase III PACIFIC trial compared durvalumab with placebo in patients unresectable, stage non-small-cell lung cancer and no disease progression after concurrent chemoradiotherapy. Consolidation was associated significant improvements the primary end points of overall survival (OS; stratified hazard ratio [HR], 0.68; 95% CI, 0.53 to 0.87; P = .00251) progression-free (PFS [blinded independent central review; RECIST v1.1]; HR, 0.52; 0.42 0.65; < .0001), manageable safety. We report updated,...
IntroductionIn the phase 3 PACIFIC study of patients with unresectable stage III NSCLC without progression after chemoradiotherapy, durvalumab demonstrated significant improvements versus placebo in primary end points progression-free survival (hazard ratio [HR] = 0.52, 95% confidence interval [CI]: 0.42–65, p < 0.0001) and overall (OS) (HR 0.68, CI: 0.53–0.87, 0.00251), manageable safety no detrimental effect on patient-reported outcomes. Here, we report 3-year OS rates for all randomized...
LBA9000 Background: EGFR TKIs are standard 1L therapy for metastatic NSCLC with sensitizing mutations; however, most patients (pts) ultimately experience PD. We report the protocol-specified final analysis (FA) from randomized, double-blind, phase 3 KEYNOTE-789 study of pemetrexed (pem) and platinum-based chemotherapy (chemo) or without pembrolizumab (pembro) as subsequent pts TKI-resistant, EGFR-mutant, nonsquamous (NCT03515837). Methods: Adults histologically cytologically confirmed stage...
8511 Background: In the placebo-controlled Phase III PACIFIC trial of patients with unresectable Stage NSCLC whose disease had not progressed after platinum-based concurrent chemoradiotherapy (cCRT), durvalumab improved overall survival (OS) (stratified hazard ratio [HR] 0.68; 95% confidence interval [CI] 0.53–0.87; p=0.0025; data cutoff [DCO] Mar 22, 2018) and progression-free (PFS) HR 0.52, CI 0.42–0.65; p<0.0001; DCO Feb 13, 2017) based on DCOs used for primary analyses, degree benefit...
Aim: Osimertinib is a third-generation, irreversible, oral EGFR tyrosine kinase inhibitor. We report real-world effectiveness and safety data. Patients & methods:EGFR T790M positive advanced non-small-cell lung cancer adults, who received ≥1 prior inhibitor, osimertinib 80 mg daily. Primary outcome: overall survival. Secondary outcomes included: investigator-assessed clinical response, progression-free survival, time-to-treatment discontinuation. Results: At data cutoff, 3015 patients had...
IntroductionThe PACIFIC trial demonstrated that durvalumab significantly improved progression-free and overall survival (PFS/OS), versus placebo, in patients with Stage III NSCLC stable or responding disease following concurrent, platinum-based chemoradiotherapy (CRT). A range of CT RT regimens were permitted, used, the trial. We report post-hoc, exploratory analyses clinical outcomes from according to CRT-related variables.MethodsPatients randomized 2:1 (1–42 days post-CRT) up 12 months (10...
Significance A previously unrecognized role is described for collagen XVIII—a ubiquitous, structurally complex basement membrane proteoglycan—in supporting preadipocyte differentiation and the maintenance of this differentiated state, hence size lipid-clearing/storage functions white adipose tissue depots. Specific lack medium long isoforms nonfibrillar in mice led to reduced adiposity, ectopic deposition fat liver, elevated very low-density lipoprotein-triglyceride levels. The finding a...
The phase III PACIFIC trial (NCT02125461) established consolidation durvalumab as standard of care for patients with unresectable, stage non-small-cell lung cancer (NSCLC) and no disease progression following chemoradiotherapy (CRT). In some cases, IIIA-N2 NSCLC are considered operable, but the relative benefit surgery is unclear. We report a post hoc, exploratory analysis clinical outcomes in trial, or without NSCLC.Patients after ≥2 cycles platinum-based, concurrent CRT were randomized 2 :...
SUMMARY Cell surface glycosaminoglycans (GAGs) play an important role in the attachment and invasion process of a variety intracellular pathogens. We have previously demonstrated that heparan sulfate proteoglycans (HSPG) mediate trypomastigote forms Trypanosoma cruzi cardiomyocytes. Herein, we analysed whether GAGs are also implicated amastigote invasion. Competition assays with soluble revealed treatment T. amastigotes heparin leads to reduction infection ratio, achieving 82% 65% inhibition...
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of digestive tract, and this disease has served as a paradigmatic model for successful rational development targeted therapies. The introduction tyrosine kinase inhibitors with activity against KIT/PDGFRA in both localized advanced stages remarkably improved survival formerly deemed resistant to all systemic Spanish Society Medical Oncology (SEOM) guidelines provide multidisciplinary updated consensus diagnosis...
For patients with recurrent glioblastoma (rGBM), there are few options following treatment failure radiotherapy plus temozolomide. Bintrafusp alfa is a first-in-class bifunctional fusion protein composed of the extracellular domain TGF-βRII receptor (a TGF-β "trap") fused to human IgG1 antibody blocking PD-L1.In this phase I, open-label expansion cohort (NCT02517398), rGBM that progressed after temozolomide received bintrafusp 1200 mg Q2W until disease progression, unacceptable toxicity, or...
Key points Extracellular matrix is highly remodelled in obesity and associates with the development of metabolic disorders, such as insulin resistance. Previously, we have shown that lack specific collagen XVIII isoforms impairs adipocyte differentiation mice. Here, show mice lacking medium long develop resistance glucose intolerance elevated serum triglycerides fat accumulation liver. We report XVIII‐deficient increased heat production at low temperatures. These results reveal a new role...
Objectives The objective of this study was to assess the intraoperative analgesic effect preoperative infiltration incision site with lidocaine or a mixture bupivacaine in cats undergoing ovariohysterectomy (OHE). Methods This prospective, randomised clinical study. Healthy female intact (n = 75) OHE under medetomidine–ketamine–buprenorphine anaesthesia were assigned randomly into three treatment groups 25 per group) receive one two local protocols placebo preoperatively midline incision:...
The European Code against Cancer recommends not to smoke, avoid alcohol consumption, eat a healthy diet, and maintain weight prevent cancer. To what extent is the public aware of influence these lifestyle factors on cancer development? goal current study was describe perceived four (tobacco, alcohol, weight) development in general population identify related low perceptions influence. We analyzed data from 2020 Onco-barometer (n = 4769), representative population-based survey conducted...
Debulking surgery, followed by taxane/platinum-based chemotherapy has traditionally been the first-line treatment for advanced ovarian cancer. However, most patients will experience recurrence afterwards, and receive subsequent lines of therapy. It proposed that extending treatment-free interval platinum can improve response to a platinum-based chemotherapy, reduce associated toxicities in women with recurrent, platinum-sensitive The aim was determine impact, clinical practice, trabectedin...
In the midst of pandemic, face-to-face data collection for national censuses and surveys was suspended due to limitations on mobility social distancing, limiting already scarce disability data. Responses these constraints were met with a surge high-frequency phone (HFPSs) that aimed provide timely understanding socioeconomic impacts responses pandemic. This paper provides an assessment HFPS datasets their inclusion questions evaluate visibility persons disabilities during COVID-19 We...
9059 Background: Abemaciclib is a potent and selective inhibitor of CDK4 & 6 approved for treatment HR+, HER2- metastatic breast cancer. In Phase 1 study, abemaciclib showed activity in pts with advanced and/or NSCLC. This 2 study evaluated the safety efficacy vs docetaxel Stage IV sqNSCLC previously treated platinum-based chemotherapy. Methods: multicenter, randomized, open-label trial, (200 mg PO every 12 hours daily) (75 mg/m2 on Day 1); both 21 day cycle until disease progression. Adults...
The NOA (Oncological Nutrition in Andalusia) project analyses the degree of integration and areas improvement implementing nutritional support care plans cancer patients Andalusia. aim was to analyse interventions for better management malnutrition cancer. A prospective evaluation implementation two nutrition conducted three hospitals. Data were collected from each hospital over a six-month period using an online platform. standardised plan designed hospitals Andalusia, which proposed...
9558 Background: Bintrafusp alfa (M7824) is a first-in-class bifunctional fusion protein composed of the extracellular domain TGF-βRII receptor (a TGF-β “trap”) fused to human IgG1 mAb blocking PD-L1. Interim analysis global phase 1 study (NCT02517398) found an objective response rate (ORR) 27.5% and manageable safety profile in patients with NSCLC who received bintrafusp 1200 mg 2L setting; median overall survival (OS) was not reached. Here we present longest efficacy follow-up cohort...